Free Trial
NASDAQ:CRVO

CervoMed Q1 2025 Earnings Report

CervoMed logo
$10.12 -0.07 (-0.69%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$10.00 -0.12 (-1.15%)
As of 08/15/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CervoMed EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.60
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

CervoMed Revenue Results

Actual Revenue
$1.92 million
Expected Revenue
$1.70 million
Beat/Miss
Beat by +$216.00 thousand
YoY Revenue Growth
N/A

CervoMed Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
9:30AM ET

CervoMed Earnings Headlines

Roth Capital Estimates CervoMed's Q3 Earnings (NASDAQ:CRVO)
Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should buy in this market, this token might just be it.
CervoMed's (CRVO) "Buy" Rating Reaffirmed at Chardan Capital
See More CervoMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CervoMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CervoMed and other key companies, straight to your email.

About CervoMed

CervoMed (NASDAQ:CRVO), a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

View CervoMed Profile

More Earnings Resources from MarketBeat